



# National HTA Assessment and Value Assessment in Europe

## Your speakers

**Focus: France, the Netherlands, the UK, Ireland and Germany**



**Dr Wim Goettsch**  
Zorginstituut Nederland (ZIN), THE NETHERLANDS  
EUneHTA JA3, Work Package 1 Network Coordination



**François Meyer MD**  
Haute Autorité de santé (HAS), FRANCE  
Advisor to HAS' President, International Affairs



**Prof Loïc Guillevin**  
Haute Autorité de santé (HAS), FRANCE  
Membre du Collège, Président de la Commission de la Transparence



**Thomas Müller**  
Federal Joint Committee (G-BA), GERMANY  
Head of Pharmaceuticals Department



**Mark Harries**  
MAP BioPharma Limited, GREAT BRITAIN  
Director



**Dr Alexander Natz**  
- Chair -  
EUCOPE – European Confederation of Pharmaceutical Entrepreneurs, BELGIUM  
Secretary General



**Christian Hill**  
MAP BioPharma Limited, GREAT BRITAIN  
Director Market Access & Government Affairs

---

**Thursday, 29<sup>th</sup> September 2016 – 09.00 - 17.30**

09.00

## **Value assessment of pharmaceuticals in Europe and beyond the EU borders – where are we in 2016?**

*François Meyer*

- HTA assessment in Europe – how much harmonisation is possible?
- National uptake of EUnetHTA joint rapid assessments
- Evidence generation: from early dialogues to a lifecycle approach
- EUnetHTA participation in EMA's initiatives: adaptive pathways, pilots on the use of registries, etc.

10.00 Coffee break

## **Update 2016 on national HTA assessment: major steps forward and current challenges:**

10.30

### **HTA assessment by the French HAS**

*Prof Loïc Guillevin*

11.15

### **HTA assessment by the Dutch ZIN**

*Dr Wim Goettsch*

12.00 Lunch

13.30

### **HTA assessment in the UK and Ireland: NICE, SMC, AWMSC and NCPE**

*Christian Hill*

14.15

### **HTA assessment by the German G-BA**

*Thomas Müller*

15.00 Coffee break

15.30

### **Early advice and early access in Europe**

*Thomas Müller*

- Early advice by the German G-BA
- Joint advice in Europe – how binding is it?
- Scientific and technical cooperation on HTA in Europe – EUnetHTA Joint Action 3, aims and objectives
- Early access – the challenges from an HTA point of view

16.15

### **Joint HTA assessment – a possible strategy for Europe?**

*Dr Wim Goettsch*

17.00

### **Joint Discussion: HTA assessment in Europe**

*Dr Wim Goettsch, Thomas Müller, Christian Hill, Prof Loïc Guillevin, François Meyer*

17.30 End of day one

---

**Friday, 30<sup>th</sup> September 2016**  
**09.00 - 13.00**

09.00

## **HTA assessment in practice**

*Mark Harries*

- Acceptance of surrogate parameters and of indirect comparisons in HTA/value assessment
- Case study: the four HTA bodies in the UK and Ireland in comparison with HTA assessment in Europe

10.15 Coffee break

10.30

## **Transparent prices in Europe – where are we in 2016?**

*Dr Alexander Natz*

- How transparent are prices in Europe?
- EURIPID and other projects – enhancing price transparency in Europe?
- Contracting possibilities
- Joint purchasing/joint price negotiation by payers – an upcoming trend?
- The end of differential pricing in Europe?

11.30

## **Case study: Pricing in Europe**

*Christian Hill*

- Factors that influence launch sequencing and pricing strategy in the EU
- Lessons we can learn from real-life examples

13.00 End of conference

---

## **Aims and objectives**

HTA assessment/value assessment is an essential tool in many national European healthcare systems

This conference provides thorough insights into the national procedures in France, the Netherlands, the UK, Ireland and Germany.

It also provides a sound update on the European harmonisation efforts in terms of joint advice or joint HTA assessments.

Pricing and pricing strategies will round off the conference, enabling you to optimise your market access strategy for the various European markets.

---

## **Who should attend?**

This conference addresses the needs of employees in the pharmaceutical industry who are responsible for market access activities in the various national European markets.

Those involved in value assessment preparation and pricing activities will benefit particularly from this conference.

Registration under  
service@forum-institut.com or  
Fax +49 6221 500-555

## Registration Form

Yes, I will attend the Conference  
☐ National HTA Assessment and  
Value Assessment in Europe

\_\_\_\_\_  
Name

\_\_\_\_\_  
Position/Department

\_\_\_\_\_  
Company

\_\_\_\_\_  
Street

\_\_\_\_\_  
Postal Code/City/Country

\_\_\_\_\_  
Tel. No.

\_\_\_\_\_  
E-Mail

\_\_\_\_\_  
Contact person at office

\_\_\_\_\_  
Date, Signature

## How to register

**Registration: +49 6221 500-500**  
**Conference-No. 16 09 235**

### Internet:

www.forum-institut.com

### Date/Venue:

29<sup>th</sup> - 30<sup>th</sup> September 2016 in Berlin  
Sofitel Berlin Kurfürstendamm  
Augsburger Str. 41 · 10789 Berlin  
T: +49 30 800999-0 · F: +49 30 800999-99

### Fee:

€ 1,590.00 (+ German VAT)

The fee includes course documentation (incl. free download) as well as midsession refreshments, lunch and certificate. Invoice and confirmation will be forwarded to you.

### Hotel accommodation:

A limited number of rooms have been reserved at the hotel and are subject to availability. Please book at least six weeks prior to the seminar to obtain a hotel room at the discounted rate. All bookings should be made directly with the hotel quoting Forum-Institut and the Seminar-No.

## Any further questions?



Please feel free to contact me if you have any questions.

**Dr. Henriette Wolf-Klein**  
Conference Manager  
Tel. +49 6221 500-680  
h.wolf-klein@forum-institut.de

## Cancellation Policy

Our general terms and conditions apply (as of 1 January 2016) and are available upon request. We can send them to you anytime or you can find them on the internet at [www.forum-institut.de/agb\\_en](http://www.forum-institut.de/agb_en)